Literature DB >> 3307558

Medical therapy of altitude illness.

P H Hackett, R C Roach.   

Abstract

Acute mountain sickness (AMS) and high-altitude pulmonary edema (HAPE) continue to cause significant morbidity and occasional deaths among mountain recreationists and residents. Descent to lower altitude is still considered the treatment of choice, but an increased role for medical therapy is emerging. Acetazolamide is currently the drug of choice for prevention of AMS, and probably HAPE as well. Numerous studies have demonstrated the drug's effectiveness when it is started 12 to 24 hours before ascent. Suggestions for indications, dosage, and regimen vary with different authors. Lower dosage offers adequate protection with fewer side effects. Acetazolamide has still not been adequately studied for treatment of altitude illness. Oxygen effectively treats HAPE and mild AMS, but is not as useful for cerebral edema. Dexamethasone recently was found effective for treatment of AMS, including early cerebral edema, but not for advanced cerebral edema. Side effects limit its use for prophylaxis, but dexamethasone offers an alternative to acetazolamide for those with sulfa intolerance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3307558     DOI: 10.1016/s0196-0644(87)80744-8

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  Preventing and treating acute mountain sickness.

Authors:  A J Ellsworth
Journal:  West J Med       Date:  1989-02

2.  Susceptibility to high-altitude pulmonary edema is associated with increased pulmonary arterial stiffness during exercise.

Authors:  A Mulchrone; H Moulton; M W Eldridge; N C Chesler
Journal:  J Appl Physiol (1985)       Date:  2019-12-19

3.  Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier.

Authors:  A J Ellsworth; E F Meyer; E B Larson
Journal:  West J Med       Date:  1991-03

4.  Sleep and Breathing at High Altitude.

Authors:  Himanshu Wickramasinghe; James D. Anholm
Journal:  Sleep Breath       Date:  1999       Impact factor: 2.816

5.  Dissecting Low Atmospheric Pressure Stress: Transcriptome Responses to the Components of Hypobaria in Arabidopsis.

Authors:  Mingqi Zhou; Jordan B Callaham; Matthew Reyes; Michael Stasiak; Alberto Riva; Agata K Zupanska; Mike A Dixon; Anna-Lisa Paul; Robert J Ferl
Journal:  Front Plant Sci       Date:  2017-04-10       Impact factor: 5.753

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.